Group 1 - The core viewpoint of the article is the legal opinion regarding Shenzhen Kaili Biomedical Technology Co., Ltd.'s 2025 Restricted Stock and Stock Option Incentive Plan, which aims to establish a long-term incentive mechanism to attract and retain talent while aligning the interests of shareholders, the company, and employees [2][4][6] - The incentive plan includes a total of 5.8818 million shares, accounting for approximately 1.36% of the company's total share capital at the time of the announcement [7][10] - The plan consists of two parts: the second category of restricted stock incentive plan and the stock option incentive plan, with specific conditions for granting and vesting [6][10] Group 2 - The company is a publicly listed entity with a registered address in Shenzhen, engaged in the development and production of medical devices and related software [4][8] - The company has been in operation since its initial public offering on April 6, 2017, under the stock code "300633" [4] - The legal opinion confirms that the company meets the necessary conditions for implementing the stock incentive plan and does not fall under any prohibitive circumstances as outlined in relevant regulations [5][10] Group 3 - The vesting conditions for the restricted stock include performance targets based on net profit growth rates over the years 2025 to 2028, with specific percentage increases required for each vesting period [19][23] - The granting price for the restricted stock is set at no less than 15.93 yuan per share, determined based on the average trading price prior to the announcement [17][18] - The plan outlines a comprehensive assessment system at the company, departmental, and individual levels to evaluate performance and determine the vesting of shares [24][26]